Eyenovia (EYEN) Competitors $0.51 +0.02 (+4.09%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EYEN vs. MRKR, MCRB, TELO, ACRS, ADAG, ANVS, RANI, TLSA, DERM, and PDSBShould you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Marker Therapeutics (MRKR), Seres Therapeutics (MCRB), Telomir Pharmaceuticals (TELO), Aclaris Therapeutics (ACRS), Adagene (ADAG), Annovis Bio (ANVS), Rani Therapeutics (RANI), Tiziana Life Sciences (TLSA), Journey Medical (DERM), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry. Eyenovia vs. Marker Therapeutics Seres Therapeutics Telomir Pharmaceuticals Aclaris Therapeutics Adagene Annovis Bio Rani Therapeutics Tiziana Life Sciences Journey Medical PDS Biotechnology Eyenovia (NASDAQ:EYEN) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings. Does the media favor EYEN or MRKR? In the previous week, Eyenovia's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score. Company Overall Sentiment Eyenovia Neutral Marker Therapeutics Neutral Does the MarketBeat Community prefer EYEN or MRKR? Eyenovia received 101 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 65.53% of users gave Eyenovia an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformEyenoviaOutperform Votes17365.53% Underperform Votes9134.47% Marker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Is EYEN or MRKR more profitable? Marker Therapeutics has a net margin of -278.27% compared to Eyenovia's net margin of -116,506.25%. Marker Therapeutics' return on equity of -78.91% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets Eyenovia-116,506.25% -547.46% -121.89% Marker Therapeutics -278.27%-78.91%-66.10% Do institutionals and insiders believe in EYEN or MRKR? 25.8% of Eyenovia shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 7.1% of Eyenovia shares are held by insiders. Comparatively, 17.4% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has stronger valuation and earnings, EYEN or MRKR? Marker Therapeutics has higher revenue and earnings than Eyenovia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyenovia$31.41K1,038.24-$27.26M-$0.80-0.64Marker Therapeutics$3.31M9.86-$8.24MN/AN/A Which has more volatility & risk, EYEN or MRKR? Eyenovia has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Do analysts recommend EYEN or MRKR? Eyenovia presently has a consensus target price of $12.00, indicating a potential upside of 2,257.56%. Marker Therapeutics has a consensus target price of $19.00, indicating a potential upside of 419.13%. Given Eyenovia's stronger consensus rating and higher probable upside, equities research analysts clearly believe Eyenovia is more favorable than Marker Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyenovia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEyenovia beats Marker Therapeutics on 8 of the 14 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Eyenovia News Delivered to You Automatically Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYEN vs. The Competition Export to ExcelMetricEyenoviaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.42M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.6410.05116.1015.23Price / Sales1,038.24400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book2.555.594.775.07Net Income-$27.26M$153.56M$119.06M$225.46M7 Day Performance-5.60%0.13%0.80%0.37%1 Month Performance5.40%15.23%5.65%3.57%1 Year Performance-64.65%41.14%36.75%29.43% Eyenovia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYENEyenovia2.9442 of 5 stars$0.51+4.1%$12.00+2,257.6%-63.9%$31.42M$31,405.00-0.6440MRKRMarker Therapeutics3.5627 of 5 stars$4.05-0.5%$19.00+369.1%+28.9%$36.31M$3.31M0.0060MCRBSeres Therapeutics3.8449 of 5 stars$0.82+5.1%$5.08+520.1%-42.9%$133.23M$126.32M-0.69233Upcoming EarningsGap DownTELOTelomir PharmaceuticalsN/A$4.06-7.9%N/AN/A$130.58MN/A0.001Positive NewsGap UpACRSAclaris Therapeutics3.3165 of 5 stars$1.81+0.6%$9.00+397.2%-58.9%$128.99M$32.02M-2.2186Upcoming EarningsPositive NewsADAGAdagene3.2917 of 5 stars$2.85-9.5%$5.00+75.4%+127.6%$126.17M$815,746.000.00260Positive NewsGap DownANVSAnnovis Bio2.2307 of 5 stars$9.30-2.6%$32.17+245.9%+44.9%$124.67MN/A-1.823Short Interest ↑RANIRani Therapeutics3.1035 of 5 stars$2.29-1.3%$11.71+411.5%+20.9%$123.90M$2.72M-1.94110Gap UpTLSATiziana Life Sciences1.451 of 5 stars$0.98-17.0%N/A+44.6%$121.64MN/A0.008News CoverageGap DownDERMJourney Medical3.4338 of 5 stars$5.75+0.5%$9.38+63.0%N/A$118.66M$79.18M-287.5090Upcoming EarningsShort Interest ↓PDSBPDS Biotechnology0.8486 of 5 stars$3.19-0.6%$14.25+346.7%-23.4%$118.38MN/A-2.6120Analyst Upgrade Related Companies and Tools Related Companies MRKR Competitors MCRB Competitors TELO Competitors ACRS Competitors ADAG Competitors ANVS Competitors RANI Competitors TLSA Competitors DERM Competitors PDSB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EYEN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
